Through our relentless dedication, we have emerged as frontrunners in the fields of oncology, hematology, transplant cases, and rare diseases. Since 2004, we have proudly partnered with over 10 international companies and extended our reach to several other Latin American nations.
Our primary focus is on developing and manufacturing high-quality pharmaceuticals, driven by an unwavering commitment to optimizing patient care. Our distinguished reputation stems from long-standing collaborations with the medical and scientific communities, where we prioritize innovation and continuous improvement in line with rigorous international quality standards.
registered
products worldwide
products in
Latin America
Our genomic test myChoice CDx Plus has been recognized by the ESGO-ESMO-ESP 2024 consensus with a Level of Evidence 1A.
Varifarma launched GORAX® (Relugolix) at the International Symposium “Advances in Urology 2024” organized by the Argentine Society of Urology.
We Launched Gorax (Relugolix) 120mg, the first LHRH antagonist with oral intake in Argentina.
Developed by Varifarma, Gorax is a revolutionary breakthrough in advanced prostate cancer treatment.
A new therapeutic alternative with multiple indications arrives to Varifarma!
We continue to increase our treatment options for our patients! We’re launching Tepadina 400mg.
Explorando los avances pioneros en el tratamiento de la Leucemia Linfoblástica Aguda (LLA), Varifarma dió el presente en el reciente curso de la Sociedad Peruana de Hematología sobre Inmunoterapia con Blinatumomab. La destacada presentación de la Dra. Laura Garcia de México resaltó el papel fundamental de esta innovadora terapia y la importancia del perfilamiento preciso de los pacientes.
We support the Argentine Society of Hematology in the continuous medical education of professionals.
